ReviewCurrent clinical pharmacology2012
Bacterial vaginosis, Atopobium vaginae and nifuratel.
Review in Current clinical pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Bacterial Load ofMicroorganisms · 2026Article
- Role of antidiarrheal agents nifuroxazide in antitumor multi‑target anticancer, multi‑mechanism anticancer drug (Review).Oncology letters · 2025Review
- Nifuratel Induces Triple-Negative Breast Cancer Cell G2/M Phase Block and Apoptosis by Regulating GADD45A.Pharmaceuticals (Basel, Switzerland) · 2024Article
- An insight into the vaginal microbiome of infertile women in Bangladesh using metagenomic approach.Frontiers in cellular and infection microbiology · 2024Article
- Nifuratel reducesMicrobiology spectrum · 2023Article
- Research of cervical microbiota alterations with human papillomavirus infection status and women age in Sanmenxia area of China.Frontiers in microbiology · 2022Article
- Finding a Balance in the Vaginal Microbiome: How Do We Treat and Prevent the Occurrence of Bacterial Vaginosis?Antibiotics (Basel, Switzerland) · 2021Review
- Comparative metagenomic analysis of the vaginal microbiome in healthy women.Synthetic and systems biotechnology · 2021Article
- Microbiome of the lower genital tract in Chinese women with endometriosis by 16s-rRNA sequencing technique: a pilot study.Annals of translational medicine · 2020Article
- Cervicovaginal Microbiome and Urine Metabolome Paired Analysis Reveals Niche Partitioning of the Microbiota in Patients with Human Papilloma Virus Infections.Metabolites · 2020Article
- Antibiotic resistance genes in the Actinobacteria phylum.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2019Review
- An update on the role of Atopobium vaginae in bacterial vaginosis: what to consider when choosing a treatment? A mini review.Archives of gynecology and obstetrics · 2019Review
- Urinary symptoms are associated with certain urinary microbes in urogynecologic surgical patients.International urogynecology journal · 2018Article
- Microbiota dysbiosis is associated with HPV-induced cervical carcinogenesis.Oncology letters · 2018Article
- Nifuratel, a novel STAT3 inhibitor with potent activity against human gastric cancer cells.Cancer management and research · 2017Article
- Crystal Structure of Glyceraldehyde-3-Phosphate Dehydrogenase from the Gram-Positive Bacterial PathogenFrontiers in microbiology · 2017Article
- The Human Microbiome during Bacterial Vaginosis.Clinical microbiology reviews · 2016Review
- Maternal Microbiome and Pregnancy Outcomes That Impact Infant Health: A Review.Advances in neonatal care : official journal of the National Association of Neonatal Nurses · 2015Review
- Probiotics and pregnancy.Current diabetes reports · 2015Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As bacterial vaginosis (BV) is a potential cause of obstetric complications and gynecological disorders, there is substantial interest in establishing the most effective treatment. Standard treatment - metronidazole or clindamycin, by either vaginal or oral route � is followed by relapses in about 30% of cases, within a month from treatment completion. This inability to prevent recurrences reflects our lack of knowledge on the origins of BV. Atopobium vaginae has been recently reported to be associated with BV in around 80% of the cases and might be involved in the therapeutic failures. This review looks at the potential benefits of nifuratel against A. vaginae compared to the standard treatments with metronidazole and clindamycin. In vitro, nifuratel is able to inhibit the growth of A. vaginae, with a MIC range of 0.125-1 μg/mL; it is active against G. vaginalis and does not affect lactobacilli. Metronidazole is active against A. vaginae only at very high concentrations (8-256 μg/mL); it is partially active against G. vaginalis and also has no effect on lactobacilli. Clindamycin acts against A. vaginae with an MIC lower than 0.125 μg/mL and is active on G. vaginalis but it also affects lactobacilli, altering the vaginal environment. These observations suggest that nifuratel is probably the most valid therapeutic agent for BV treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.